Coagulation Factor II Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor II (prothrombin). It is manufactured by immunoabsorption and contains a residual factor concentration of 1% prothrombin activity and normal levels of fibrinogen and other extrinsic clotting factors. Coagulation Factor II Deficient Plasma was designed to be used in combination with Dade Innovin or Thromborel S Reagents.

Coagulation Factor V Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor V. It is manufactured by immunoabsorption and contains a residual factor concentration of 1% factor V activity and normal levels of fibrinogen and other extrinsic clotting factors. Coagulation Factor V Deficient Plasma was designed to be used in combination with Dade Innovin or Thromborel S Reagents.

Coagulation Factor VII Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor VII. It is manufactured by immunoabsorption and contains a residual factor concentration of 1% factor VII activity and normal levels of fibrinogen and other extrinsic clotting factors. Coagulation Factor VII Deficient Plasma was designed to be used in combination with Dade Innovin or Thromborel S Reagents.

Coagulation Factor VIII Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor VIII (haemophilia A). With a residual factor activity of less than 1%, the reagent is ideal for the monitoring of substitution therapy. Coagulation Factor VIII Deficient Plasma was designed to be used in combination with Dade Actin, Dade Actin FS, Dade Actin FSL, or Pathromtin SL Reagents.

Coagulation Factor IX Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor IX (haemophilia B). With a residual factor activity of less than 1%, the reagent is ideal for the monitoring of substitution therapy. Coagulation Factor IX Deficient Plasma was designed to be used in combination with Dade Actin, Dade Actin FS, Dade Actin FSL, or Pathromtin SL Reagents.

Coagulation Factor X Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor X. It is manufactured by immunoabsorption and contains a residual factor concentration of less than 1% factor X activity and normal levels of fibrinogen and other extrinsic clotting factors. Coagulation Factor X Deficient Plasma was designed to be used in combination with Dade Innovin or Thromborel S Reagents.

Coagulation Factor XI Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor XI. The reagent has a residual factor concentration of less than 1% factor XI activity and was designed to be used in combination with Dade Actin, Dade Actin FS, Dade Actin FSL, or Pathromtin SL Reagents.

Coagulation Factor XII Deficient Plasma is a human plasma-based reagent for the detection of hereditary or acquired deficiencies of factor XII. The reagent has a residual factor concentration of less than 1% factor XII activity and was designed to be used in combination with Dade Actin, Dade Actin FS, Dade Actin FSL, or Pathromtin SL Reagents.

160 µmol/L of ADP. Investigation of platelet aggregation induced by ADP.

0.8 mmol/L of Epinephrine. Investigation of platelet aggregation induced by Epinephrine.

12 mmol/L of Arachidonic Acid. Investigation of platelet aggregation induced by Arachidonic Acid.

12 mg/mL of Ristocetin. Measurement of the von Willebrand Factor Ristocetin cofactor by platelet aggregation.

0.8 mg/mL of Collagen. Investigation of platelet aggregation induced by Collagen.

LA 1 Screening Reagent contains dilute Russell’s viper venom and low phospholipids for use in the simplified DRVVT as a screening test for lupus anticoagulants. The LA 1 Screening Reagent was designed to be used in conjunction with the LA 2 Confirmation Reagent.

LA 2 Confirmation Reagent is a simplified dilute Russell’s viper venom test rich in phospholipids, making it ideal for the confirmation of lupus anticoagulants. The LA 2 Confirmation Reagent was designed to be used in conjunction with the LA 1 Screening Reagent.

The INNOVANCE D-Dimer Kit is a rapid, highly precise, and sensitive test system for the determination of D-dimer. It offers high diagnostic sensitivity of >98% for exclusion of VTE (venous thromboembolism). With its extended assay range, D-dimer levels can be used for the diagnosis and monitoring of patients with disseminated intravascular coagulopathy (DIC), as well as for the monitoring of anticoagulation treatment and pregnancy-related coagulopathies (e.g., preeclampsia and HELLP syndrome).

Protein C Reagent is a coagulometric reagent used for the quantitative determination of protein C activity. The reagent is suitable for the detection of hereditary or acquired protein C deficiencies.

The Berichrom Protein C Kit, a chromogenic activity assay, is used for the detection of hereditary or acquired protein C deficiency types. The assay is also used for the monitoring of substitution therapy with protein C concentrates in congenital protein C deficiency. The Berichrom Protein C Kit is less susceptible to interfering substances than a clotting assay.

ProC Global Kit is a coagulometric screening reagent for the protein C pathway. It provides a determination of the anticoagulatory capacity of the protein C system. The heparin-insensitive reagent is useful in screening individuals affected by thrombophilia. ProC Global Kit is sensitive to deficiencies of factor V Leiden and proteins C and S, certain lupus anticoagulants, and high factor VIII levels. When use in combination with FV deficient plasma, it screen for the detection of factor V Leiden.

Protein S Ac Reagent, a coagulometric activity reagent, is used for the detection of hereditary or acquired protein S deficiencies.

The INNOVANCE Free PS Ag Kit is an easy-to-use, highly specific, and stable test for the quantitative detection of free protein S in human plasma. It is based on monoclonal antibodies and employs polystyrene particles covalently coated with two monoclonal antibodies (mAb A and mAb B) that have high specificity for free protein S and do not bind to protein S/C4b-binding protein complexes; the high specificity also shows no major interferences, including interferences commonly incurred from rheumatoid factors and heterophilic antibodies. The ready-to-use liquid reagent provides excellent stability performance as well as precision.

The INNOVANCE Antithrombin Kit is an automated chromogenic assay for the quantitative determination of functional antithrombin. The human factor Xa-based reagent has minimal interference with heparin cofactor II and thrombin inhibitors such as hirudin. The ready-to-use liquid reagents provide excellent precision and reliability.

vWF Ag Kit contains is a quantitative, automated immunoassay used to determine the differentiation of quantitative versus qualitative von Willebrand factor deficiencies. It is sensitive to type 1 and 3 VWF deficiencies and offers a wide measuring range of 2–600%.

The INNOVANCE VWF Ac Kit is a sensitive, reliable, and convenient test system for direct determination of VWF activity. It employs an advanced new technology that allows the assay to mimic the way in which VWF binds to glycoprotein Ib (GPIb), the major VWF receptor protein on platelets. Latex particles are coated with an antibody against GPIb, to which recombinant GPIb is added. The addition of patient plasma induces a VWF-dependent agglutination, which is detected turbidimetrically. Because the recombinant receptor protein includes two gain-of-function mutations, the assay does not require ristocetin.

BC von Willebrand Reagent provides a simple, rapid, and automated procedure for the determination of the ristocetin cofactor activity of von Willebrand factor. The reagent, which provides a rapid measurement time, is sensitive to types 1, 2, and 3 of von Willebrand disease (except VWD 2N) and is the recommended screening method for von Willebrand disease.